Blood
Articles in this Issue
Analysis of predictive factors for POD24 in patients with previously untreated mantle cell lymphoma receiving bendamustine-rituximab with or without acalabrutinib in the phase 3 ECHO trial
Abstract Introduction: In mantle cell lymphoma (MCL), clinical progression of disease within 24 months of treatment initiation (POD24) is ass...
Hematological and clinical improvements with elritercept (KER-050, TAK-226) at the recommended Phase 2 dose (RP2D) in patients with myelofibrosis (MF) receiving ruxolitinib: Updated results from the Phase 2 restore trial
Abstract Background Anemia is a hallmark of MF, contributing to fatigue, transfusion dependence, and reduced survival. Janus kinase (JAK) in...
First-in-human study of CTX130, a CD70-directed allogeneic CAR T therapy, in adult T-cell leukemia/lymphoma: Clinical and genomics findings from a long-term follow-up of subgroup analysis from the cobalt-LYM Phase 1 trial
Abstract Introduction Adult T-cell leukemia/lymphoma (ATLL) is a rare and aggressive malignancy of CD4+ T cells, linked...
Multiple myeloma with ≥1% circulating plasma cells in peripheral blood has a poor prognosis
Abstract [Introduction] Plasma cell leukemia (PCL) is a rare and aggressive form of plasma cell dyscrasia, historically...
Single-cell transcriptomic insights into venetoclax response and resistance in secondary AML evolving from MDS
Abstract Background: Venetoclax (VEN), a selective BCL-2 inhibitor, has improved outcomes in AML when combined with hypomethylating agents (...
Optimizing anticoagulation for hospitalized children: A single-institution pediatric anticoagulation stewardship experience
Abstract Introduction: Children are at increased risk for preventable anticoagulation-related adverse events due to vari...
Longitudinal genomic and cytogenetic dynamics in myelodysplastic syndromes (MDS): Insights into clonal evolution and disease progression
Abstract Background: Myelodysplastic syndrome (MDS) is a heterogeneous clonal hematopoietic disorder, with variable risk of progression to s...
Preclinical and clinical Study of olverembatinib in patients with myeloid/lymphoid neoplasms with FGFR1 rearrangement
Abstract Introduction Myeloid/lymphoid neoplasms with FGFR1 rearrangement (MLN-FGFR1) constitute an aggressive stem-cell derived myeloprolif...
Preliminary data from the ongoing Phase 1 study of the menin-MLL inhibitor enzomenib (DSP-5336) in combination with venetoclax and azacitidine in patients with relapsed or refractory Acute Myeloid Leukemia
Abstract Introduction: Venetoclax and azacitidine (VEN/AZA) is a standard backbone regimen for older/unfit patients (pts) with newly diagnos...
Assessment of the angiogenic proteins placental growth factor (PlGF) and soluble fms-like tyrosine kinase 1 (sFlt-1) in patients with hereditary spherocytosis
Abstract Background: Hereditary spherocytosis (HS) is a rare genetic disorder characterized primarily by hemolytic anemia, jaundice, splenom...
FLAG/VEN as a frontline induction therapy for AML: A multi-centre experience of Anthracycline free approach from India
Abstract Introduction: Acute myeloid leukemia (AML) is a life-threatening hematological malignancy with reported 5-year OS of 40% to 50% wit...
Non-cancer related mortality in hematological cancers: A nation-wide population based study
Abstract Introduction Hematological cancers—including leukemias, lymphomas, plasma cell disorders, myelodysplastic syndr...
7-day venetoclax combined with intensive chemotherapy as induction treatment in high-risk newly diagnosed Acute Myeloid Leukemia
Abstract INTRODUCTION Acute myeloid leukemia (AML) in the high-risk group accounts for about 40-50% of adult acute myeloid leukemia, with a...
Daratumumab, bortezomib, thalidomide and dexamethasone improves renal outcomes in multiple myeloma transplant eligible patients presenting with renal failure: A real life experience from northeastern Italy
Abstract Introduction: Renal impairment (RI) in multiple myeloma (MM) is defined by IMWG as creatinine >2 mg/dL (170 umol/L) or creat...
Dietary fiber intake improves survival in allogeneic HCT patients and exhibits synergistic effects with taurine supplementation in preclinical models
Abstract Background Dietary fiber modulates the intestinal microbiome, enhancing production of short-chain fatty acids (SCFAs) and bile acid...
Trial in progress - a randomized study of ASTX727 with or without Iadademstat in accelerated/blast-phase myeloproliferative neoplasms
Abstract Introduction and Rationale: Philadelphia chromosome-negative (Ph-) myeloproliferative neoplasms (MPNs) are hematopoietic stem cell d...
Anthracyclines induce epigenetic changes in ALDH1A that promote chemoresistance in AML, revealing a potential treatment strategy co-targeting ALDH1A inhibition with hypomethylating agents
Abstract Background: Relapse/Refractory Acute Myeloid Leukemia (R/R AML) is a condition where patients do not achieve complete remission aft...
Burden of vitamin d deficiency and bone health risk factors in persons with von Willebrand disease in Arkansas
Abstract Background: Vitamin D is an essential fat-soluble vitamin, and its deficiency can result in rickets in children and osteoporosis in...
Scalable production of stem cell–derived artificial platelets: A safe alternative in the era of blood shortage
Abstract Background Global platelet supply is facing increasing instability due to a declining donor population caused by aging societies and...
Real-world study of rituximab, methotrexate, and zanubrutinib (R-MZ) in the treatment of newly diagnosed primary central nervous system lymphoma
Abstract Objective: Primary central nervous system lymphoma (PCNSL) is a rare subtype of extra-nodal non-Hodgkin lymphoma and and there is c...
Prognostic utility of the ELTS score in pediatric chronic myeloid leukemia: Is it a valid clinical tool?
Abstract Background: Chronic myeloid leukemia (CML) is rare in children, with an estimated incidence of one per million...
Data validation and quality framework for building a european multimodal real-world dataset for clinical outcome research in sickle cell disease
Abstract Introduction Sickle cell disease (SCD) is a life-threatening autosomal recessive disorder caused by abnormal he...
Reduced-dose whole brain radiotherapy is an effective consolidation strategy for parenchymal-only secondary cns lymphoma
Abstract Introduction: While optimal consolidation strategies for patients with secondary central nervous system lymphoma (SCNSL) remain deb...
Frailty markers associated with impaired survival and hospitalization outcomes for patients with aggressive B-cell lymphoma receiving CAR T-cell therapy
Abstract Patients undergoing chimeric antigen receptor t-cell (CAR-T) therapy face unique toxicities and hospitalization outcomes that vary...
Prognostic significance of pretreatment neutrophil-to- lymphocyte ratio for overall survival in primary myelofibrosis:updated data from Azerbaijan.
Abstract Objective. Consequently, activation of the Jak-STAT pathway plays a central role in the pathogenesis of primary myelofibrosis and r...